HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Acelyrin (NASDAQ:SLRN) and maintained a $30 price target for the company's stock.
November 28, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar reaffirmed a Buy rating on Acelyrin and kept the price target at $30, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a $30 price target by a reputable analyst could lead to increased investor confidence and a potential short-term uplift in Acelyrin's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100